⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Liraglutide

لیراگلوتاید

⚠ Unverified

🍽️ Alimentary Tract And MetabolismGLP-1 receptor agonist

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:No specific problem stated 🇮🇷 Registered in Iran ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA022341 ATC A10BJ02

Market / country: 🇺🇸 USA

Victoza (US)

🧮 Dose calculator

Disease / regimen

Type 2 diabetes mellitus · Regimen source: FDA Victoza · 2.1

• 0.6 mg is only for GI tolerability. If more than 3 days missed, restart at 0.6 mg. FDA Victoza · 2.1 FDA Victoza · 2.2

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ Personal or family history of medullary thyroid carcinoma or MEN 2; serious hypersensitivity. FDA Victoza · 4 FDA Saxenda · 4

Warnings

• Boxed warning: thyroid C-cell tumours in rodents; contraindicated with MTC or MEN 2 history. FDA Victoza · Boxed Warning

Formulations

6 mg/mL pen (18 mg/3 mL; doses 0.6, 1.2, 1.8 mg) — injection 🇺🇸 USA FDA Victoza · 3
Saxenda 6 mg/mL pen (doses 0.6–3 mg) — injection 🇺🇸 USA FDA Saxenda · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Victoza · 8.1
“Risk Summary Based on animal reproduction studies, there may be risks to the fetus from exposure to VICTOZA during pregnancy.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Victoza · 8.2
“Risk Summary There are no data on the presence of VICTOZA in human milk, the effects on the breastfed infant, or the effects on milk production.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Victoza · 8.4
“The safety and effectiveness of VICTOZA as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus have been established in pediatric patients 10 years of age and older.”
👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Victoza · 8.5
“No overall differences in safety or effectiveness for VICTOZA have been observed between patients 65 years of age and older and younger patients.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA022341
DailyMed (FDA label)FDA Victoza
MedlinePlus (NIH)Liraglutide Injection
WHO ATC/DDDA10BJ02
Darooyab (Iran)Liraglutide

🇮🇷 Registered in Iran Darooyab · G-4899/Liraglutide

Dosage forms with Iranian generic codes, per Darooyab.

22666 · LIRAGLUTIDE INJECTION, SOLUTION 6 mg/1mL 3ML PEN (VICTOZA) · قلم تزریقی لیراگلوتاید ۶ میلی‌گرم / ۱ میلی‌لیتر ۳ میلی‌لیتر (ویکتوزا)

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Victoza · 3 FDA Saxenda · 3 FDA Victoza · 2.1 FDA Victoza · 2.2 FDA Saxenda · 2.2, Table 1 FDA Saxenda · 2.2 FDA Victoza · 4 FDA Saxenda · 4 FDA Victoza · Boxed Warning FDA Victoza · 8.1 FDA Victoza · 8.2 FDA Victoza · 8.4 FDA Victoza · 8.5 FDA Victoza · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-4899/Liraglutide
Clinical review⚠ Unverified